Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The phosphatidylinositol-3-kinase (PI3K) pathway has an essential role in signal transduction, where it is required for a number of different cellular processes including proliferation, differentiation, development, migration and growth. In the immune system, PI3K regulates inflammation by controlling the activation and recruitment of leukocytes. The generation of conditional knockout mice has allowed the study of PI3K isoforms specifically in B and T lymphocytes, and demonstrates the importance of intact signalling in their development and function. PI3K signalling must be tightly regulated in lymphocytes as excessive PI3K can lead to autoimmunity, immunodeficiency or cancer, whilst diminished signalling can result in developmental defects and immunodeficiency. Recent advances in the understanding of PI3K signalling have hastened the application of isoform-specific PI3K inhibitors, which are currently undergoing clinical trials. This review will focus on the p110δ catalytic subunit of the class 1A family of PI3K, and its role in the development and activation of B lymphocytes through various downstream effectors.

Original publication




Journal article


Adv Exp Med Biol

Publication Date





119 - 135


Animals, Autoimmunity, B-Lymphocytes, Class Ia Phosphatidylinositol 3-Kinase, Common Variable Immunodeficiency, Gene Expression Regulation, Humans, Lymphocyte Activation, Mice, Mice, Knockout, Neoplasms, Proto-Oncogene Proteins c-akt, Signal Transduction